scholarly journals IMMUNOTHERAPY BASED ON DENDRITIC CELLS IN BLADDER CANCER TREATMENT

2018 ◽  
Vol 5 (2) ◽  
pp. 16-23
Author(s):  
A. S. Ilnitskaya ◽  
A. B. Danilova ◽  
I. A. Baldueva
Keyword(s):  
Bladder Cancer ◽  
Dendritic Cells ◽  
Side Effects ◽  
Cancer Therapy ◽  
Cancer Treatment ◽  
Relevant Today ◽  
Vaccine Treatment ◽  
Antitumor Vaccine ◽  
Methods Of Treatment ◽  
Selection Of

The development of an antitumor vaccine based on autologous dendritic cells (DCs) for bladder cancer treatment is extremely relevant today due to the proven high immunological potency of this type of tumor. Vaccination with DCs-based drugs as a monotherapy or in combination with other methods of treatment has shown to be effective in cancer therapy. The vaccine administration is considered to be safe, the associated side effects are insignificant and can be characterized as undesirable phenomena of 1st or 2nd degree. There are a number of issues that arise while creating DCs vaccines that need to be carefully resolved. Among them, the problem of selecting potential targets for the vaccine treatment, the ways to enhance the potency of the vaccine, and the selection of technology for obtaining a sufficient number of functional DCs should be specifically mentioned. The review focuses on the use of autoantigen or alloantibody material for the activation of DCs, and the results of experimental and clinical studies of DCs vaccines in bladder cancer.

Medical Management of Trigeminal Neuralgia

2019 ◽  
pp. 591-609
Author(s):  
Niushen Zhang
Keyword(s):  
Side Effects ◽  
Trigeminal Neuralgia ◽  
Side Effect Profile ◽  
Clinical Use ◽  
Line Treatment ◽  
Nasal Sprays ◽  
Surgical Methods ◽  
Methods Of Treatment ◽  
First Line Treatment ◽  
Selection Of

The first-line treatment of trigeminal neuralgia can be very effective, but side effects are often difficult for patients to tolerate. This chapter is a guide to the broad selection of medical therapies currently available for the treatment of trigeminal neuralgia which includes oral therapies and other non-surgical methods of treatment such as IV medications, nasal sprays, topical ointments, and injections. The discussion of each treatment includes discussion of its evidence in current literature, its proposed mechanism of action, its dosing and appropriate setting for clinical use, and its side effect profile.

Cancer therapy with unloaded monocyte-derived dendritic cells in patients with inoperable pancreatic and gall bladder cancer

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 2569-2569
Author(s):  
T. Nesselhut ◽  
R. Y. Chang ◽  
C. Matthes ◽  
D. Marx ◽  
D. R. Lorenzen ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Dendritic Cells ◽  
Cancer Therapy ◽  
Gall Bladder ◽  
Gall Bladder Cancer

Cancer therapy with unloaded monocyte-derived dendritic cells in patients with inoperable pancreatic and gall bladder cancer

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 2569-2569 ◽  
Author(s):  
T. Nesselhut ◽  
R. Y. Chang ◽  
C. Matthes ◽  
D. Marx ◽  
D. R. Lorenzen ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Dendritic Cells ◽  
Cancer Therapy ◽  
Gall Bladder ◽  
Gall Bladder Cancer

Dr. M.S. Reddy’s Multiple Mixed Strain Probiotic Adjuvant Cancer Therapy, to Complement Immune Checkpoint Therapy and Other Traditional Cancer Therapies, with Least Auto-immune Side Effects through Eco-balance of Human Microbiome

2018 ◽  
Vol 11 (6) ◽  
pp. 4295-4317
Author(s):  
Malireddy S Reddy
Keyword(s):  
Side Effects ◽  
Cancer Therapy ◽  
Adjuvant Therapy ◽  
Cancer Treatment ◽  
Nosocomial Infections ◽  
Immune Checkpoint ◽  
Great Promise ◽  
Cancer Therapies ◽  
Immunological Mechanisms ◽  
Probiotic Strains

This paper describes a novel serendipitous discovery to successfully treat cancer with improved efficiency emerged while using Dr. M.S. Reddy’s Multiple Mixed Strain Probiotic Therapy (originally discovered to prevent or treat nosocomial infections) as an adjuvant therapy along with the immune checkpoint therapy and other conventional cancer therapies. This new discovery is named as “Dr. M.S. Reddy’s Multiple Mixed Strain Probiotic Adjuvant Cancer Therapy”. Cancer is rising as a global epidemic, currently killing over 9 million people every year. This figure is supposed to get up to 13 million by the year 2030.  The cancer epidemic is more prevalent in the Western countries than Eastern countries. The cost of treating cancer was $290 billion in the year 2010 and it is supposed to get up to $458 billion/year by the year 2030.  Recently checkpoint immune therapy is showing great promise as a treatment tool. Yet the global success in treating the cancer is only 20% or slightly higher, with all the advancements and discoveries.  A new paradigm shift in cancer treatment has been discovered as serendipitous discovery to enhance the efficiency of the existing cancer therapies significantly. This serendipitous discovery came as a surprise while running community based clinical trials using the novel discovery of Dr. M.S. Reddy’s Multiple Mixed Strain Probiotic Therapy to prevent or cure the hospital acquired or nosocomial infections, which are affecting over six million people with severe mortality.  Several physicians have observed that Dr. Reddy’s Probiotic therapy given for prevention or control of nosocomial infections significantly helped the recovery of cancer patients who were also receiving standard cancer therapies.  This article outlines the mechanism by which Dr. M.S. Reddy’s Multiple Mixed Strain Probiotic Therapy assist to cure cancer at a much faster pace, with the least side effects, when used as adjuvant therapy along with the immune checkpoint therapy, and other standard cancer therapies.  Details are presented how the PD-1 and CTLA-4 blockade therapy works to reduce cancer and also the possible scientific explanations why such an immune checkpoint therapy only works on limited cancer cases.  The effect of Multiple Mixed Strain Probiotics on establishing the immune tolerance through reduction of local or systemic inflammation is also outlined. The possible biological and immunological mechanisms of how Multiple Mixed Strain Probiotic Therapy significantly enhances the immune checkpoint therapy (PD-1 and CTLA-4 blockade) has been presented with explicit details. The details are also presented showing how Multiple Mixed Strain Adjuvant Therapy can minimize or significantly reduce the unpleasant side effects of the current conventional and immune checkpoint cancer therapies. Practical clinical and experimental data presented to show the significance of Dr. M.S. Reddy’s Multiple Mixed Strain Probiotic Therapy, as an adjuvant therapy, along with the standard cancer therapies to improve the cancer treatment efficiencies by up to 60%. Evidence is presented to illustrate and point out that the current FDA regulations will allow the use of Dr. M.S. Reddy’s Multiple Mixed Strain Probiotic (Therapy) as nutritional supplement, since the probiotic strains used are categorized as food grade and GRAS (Generally Regarded as Safe), as per the 21 Code of Federal Regulations of the Food and Drug Administration.  Details are presented with genus and species identification of individual probiotic strains used in the Multiple Mixed Strain Probiotic Therapy. Thus special and formal FDA approval is not required to use them as adjuvants to improve the efficiency of traditional cancer therapies. Finally the scientific reasoning is presented with evidence to illustrate the utmost urgency and necessity of using Dr. M.S. Reddy’s “Multiple Mixed Strain Probiotic Therapy” along with the immune checkpoint therapy and other traditional cancer therapies to protect the lives of millions of people dying with cancer annually.  

Medical Management of Trigeminal Neuralgia

2018 ◽  
pp. 45-69
Author(s):  
Niushen Zhang
Keyword(s):  
Side Effects ◽  
Trigeminal Neuralgia ◽  
Side Effect Profile ◽  
Clinical Use ◽  
Line Treatment ◽  
Nasal Sprays ◽  
Surgical Methods ◽  
Methods Of Treatment ◽  
First Line Treatment ◽  
Selection Of

The first-line treatment of trigeminal neuralgia can be very effective, but side effects are often difficult for patients to tolerate. This chapter is a guide to the broad selection of medical therapies currently available for the treatment of trigeminal neuralgia which includes oral therapies and other non-surgical methods of treatment such as IV medications, nasal sprays, topical ointments, and injections. The discussion of each treatment includes discussion of its evidence in current literature, its proposed mechanism of action, its dosing and appropriate setting for clinical use, and its side effect profile.

scholarly journals Aptamer-iRNAs as Therapeutics for Cancer Treatment

2018 ◽  
Vol 11 (4) ◽  
pp. 108 ◽  
Author(s):  
Mario Soldevilla ◽  
Daniel Meraviglia-Crivelli de Caso ◽  
Ashwathi Menon ◽  
Fernando Pastor
Keyword(s):  
Cancer Therapy ◽  
Cancer Treatment ◽  
Antisense Oligonucleotides ◽  
Tertiary Structure ◽  
Potential Treatment ◽  
High Affinity ◽  
Different Types ◽  
Systematic Evolution ◽  
Exponential Enrichment ◽  
Selection Of

Aptamers are single-stranded oligonucleotides (ssDNA or ssRNA) that bind and recognize their targets with high affinity and specificity due to their complex tertiary structure. Aptamers are selected by a method called SELEX (Systematic Evolution of Ligands by EXponential enrichment). This method has allowed the selection of aptamers to different types of molecules. Since then, many aptamers have been described for the potential treatment of several diseases including cancer. It has been described over the last few years that aptamers represent a very useful tool as therapeutics, especially for cancer therapy. Aptamers, thanks to their intrinsic oligonucleotide nature, present inherent advantages over other molecules, such as cell-based products. Owing to their higher tissue penetrability, safer profile, and targeting capacity, aptamers are likely to become a novel platform for the delivery of many different types of therapeutic cargos. Here we focus the review on interfering RNAs (iRNAs) as aptamer-based targeting delivered agents. We have gathered the most reliable information on aptamers as targeting and carrier agents for the specific delivery of siRNAs, shRNA, microRNAs, and antisense oligonucleotides (ASOs) published in the last few years in the context of cancer therapy.

scholarly journals The Two Sides of Dietary Antioxidants in Cancer Therapy

2020 ◽  
Author(s):  
Musbau Adewumi Akanji ◽  
Heritage Demilade Fatinukun ◽  
Damilare Emmanuel Rotimi ◽  
Boluwatife Lawrence Afolabi ◽  
Oluyomi Stephen Adeyemi
Keyword(s):  
Oxidative Stress ◽  
Side Effects ◽  
Cancer Therapy ◽  
Cancer Treatment ◽  
Cancer Patients ◽  
Dietary Antioxidants ◽  
Cancer Treatments ◽  
The World ◽  
Two Sides ◽  
Radiotherapy Treatment

Cancer is a major cause of mortality around the world, representing about 13% of deaths on the planet. Among the available cancer treatments, chemotherapy is most frequently utilized compared to other treatments such as surgery and radiotherapy. Many dietary antioxidants have proven to effectively prevent oxidative stress, which has been noted in many disease pathogeneses, including cancer. However, during chemotherapy or radiotherapy treatment of cancer patients, antioxidants are used as an adjuvant treatment. The use of a proof-based technique is advised in determining the supplements most suited to cancer patients. Though there are numerous opinions about the dangers and advantages of antioxidants, it is reasonable to conclude that side effects caused by antioxidants, for now, remain unclear for patients during cancer treatment, aside from smokers during radiotherapy. In this report, details of the effectiveness of antioxidants on cancer treatment aiding in the reduction of cancer therapy side effects are discussed.

scholarly journals Prediction of Bladder Cancer Treatment Side Effects Using an Ontology-Based Reasoning for Enhanced Patient Health Safety

Informatics ◽  
2021 ◽  
Vol 8 (3) ◽  
pp. 55
Author(s):  
Chamseddine Barki ◽  
Hanene Boussi Rahmouni ◽  
Salam Labidi
Keyword(s):  
Bladder Cancer ◽  
Side Effects ◽  
Cancer Treatment ◽  
Semantic Knowledge ◽  
Patient Treatment ◽  
Case Based Reasoning ◽  
Evidence Based ◽  
Potential Health ◽  
Treatment Side Effects ◽  
Knowledge Based

Predicting potential cancer treatment side effects at time of prescription could decrease potential health risks and achieve better patient satisfaction. This paper presents a new approach, founded on evidence-based medical knowledge, using as much information and proof as possible to help a computer program to predict bladder cancer treatment side effects and support the oncologist’s decision. This will help in deciding treatment options for patients with bladder malignancies. Bladder cancer knowledge is complex and requires simplification before any attempt to represent it in a formal or computerized manner. In this work we rely on the capabilities of OWL ontologies to seamlessly capture and conceptualize the required knowledge about this type of cancer and the underlying patient treatment process. Our ontology allows case-based reasoning to effectively predict treatment side effects for a given set of contextual information related to a specific medical case. The ontology is enriched with proofs and evidence collected from online biomedical research databases using “web crawlers”. We have exclusively designed the crawler algorithm to search for the required knowledge based on a set of specified keywords. Results from the study presented 80.3% of real reported bladder cancer treatment side-effects prediction and were close to really occurring adverse events recorded within the collected test samples when applying the approach. Evidence-based medicine combined with semantic knowledge-based models is prominent in generating predictions related to possible health concerns. The integration of a diversity of knowledge and evidence into one single integrated knowledge-base could dramatically enhance the process of predicting treatment risks and side effects applied to bladder cancer oncotherapy.

Sign in / Sign up

Export Citation Format

Share Document